Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $8.17 in the prior trading day, Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed at $8.33, up 1.96%. In other words, the price has increased by $1.96 from its previous closing price. On the day, 1.12 million shares were traded. OLMA stock price reached its highest trading level at $8.9 during the session, while it also had its lowest trading level at $7.66.
Ratios:
Our goal is to gain a better understanding of OLMA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.22 and its Current Ratio is at 15.22. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Citigroup on August 12, 2025, Reiterated its Buy rating but revised its target price to $21 from $20 previously.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $24. On January 30, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $20.Citigroup initiated its Buy rating on January 30, 2024, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 18 ’25 when Harmon Cyrus sold 10,000 shares for $8.33 per share. The transaction valued at 83,300 led to the insider holds 744,140 shares of the business.
Harmon Cyrus sold 10,000 shares of OLMA for $80,400 on Sep 16 ’25. The Director now owns 754,140 shares after completing the transaction at $8.04 per share. On Sep 18 ’25, another insider, Harmon Cyrus, who serves as the Director of the company, sold 3,086 shares for $8.32 each. As a result, the insider received 25,676 and left with 117,028 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 571723968 and an Enterprise Value of 214565968.
Stock Price History:
The Beta on a monthly basis for OLMA is 2.02, which has changed by -0.3399366 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, OLMA has reached a high of $13.93, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is 42.12%, while the 200-Day Moving Average is calculated to be 57.63%.
Shares Statistics:
The stock has traded on average 786.56K shares per day over the past 3-months and 1163070 shares per day over the last 10 days, according to various share statistics. A total of 68.63M shares are outstanding, with a floating share count of 52.86M. Insiders hold about 22.99% of the company’s shares, while institutions hold 85.69% stake in the company. Shares short for OLMA as of 1756425600 were 8413141 with a Short Ratio of 10.70, compared to 1753920000 on 7636164. Therefore, it implies a Short% of Shares Outstanding of 8413141 and a Short% of Float of 13.489999999999998.
Earnings Estimates
The stock of Olema Pharmaceuticals Inc (OLMA) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.4 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.58 and -$2.27 for the fiscal current year, implying an average EPS of -$1.81. EPS for the following year is -$2.0, with 6.0 analysts recommending between -$1.37 and -$2.37.
